Antiviral medications for influenza
Pro Research Analysisby 
Searched over 200M research papers
Antiviral Medications for Influenza: Key Drug Classes and Effectiveness
Neuraminidase Inhibitors: Oseltamivir, Zanamivir, Peramivir, Laninamivir
Neuraminidase inhibitors (NAIs) such as oseltamivir, zanamivir, peramivir, and laninamivir are widely used for treating influenza. Early initiation of these drugs, ideally within 48 hours of symptom onset, is crucial for better outcomes, including faster recovery and reduced complications Chan2023Fiore2011. Oseltamivir and zanamivir may reduce mortality, hospitalizations, and symptom duration, especially in high-risk populations, though the overall certainty of these benefits is low to moderate Hsu2012Fiore2011. Direct comparisons show no major differences in effectiveness between oseltamivir and zanamivir . Peramivir and laninamivir are also effective, but less data is available on their comparative benefits Chan2023Świerczyńska2022.
Endonuclease Inhibitor: Baloxavir Marboxil
Baloxavir marboxil is a newer antiviral with a different mechanism of action. It is as safe and effective as NAIs and may reduce the risk of hospital admission and shorten symptom duration, particularly in high-risk patients, without increasing adverse events Świerczyńska2022Gao2025. Baloxavir is especially notable for its single-dose regimen and its ability to reduce viral load quickly Chan2023Świerczyńska2022Gao2025.
M2 Inhibitors: Amantadine and Rimantadine
Amantadine and rimantadine are older drugs that target the M2 protein of influenza A viruses. Amantadine may reduce mortality and pneumonia in influenza A, but resistance is common, and these drugs are not effective against influenza B Hsu2012De Clercq2006. Due to high resistance rates, their use is now limited Hayden2008De Clercq2006.
Emerging and Investigational Antivirals
Several new antivirals are in late-stage clinical trials, including nitazoxanide, DAS181, T-705 (favipiravir), and monoclonal antibodies targeting the hemagglutinin stem. These drugs have different mechanisms, such as targeting host cell factors or viral polymerase, and may offer improved effectiveness, especially when used in combination with existing drugs like oseltamivir Koszalka2017Hayden2008Naesens2016. Combination therapy is being studied and may provide better outcomes, but more clinical data is needed Koszalka2017Świerczyńska2022Hayden2008.
Resistance and Combination Therapy
Resistance to NAIs and M2 inhibitors can develop, but it generally does not have a major impact on patient recovery with current drugs Chan2023Hayden2008. Combination therapy with new and existing antivirals is under investigation and may help overcome resistance and improve treatment outcomes Koszalka2017Hayden2008Naesens2016.
Prophylaxis and Transmission Prevention
Antiviral medications are also used for post-exposure prophylaxis in specific populations to prevent influenza transmission, especially in close contacts of infected individuals Chan2023Fiore2011. Early treatment and prophylaxis are important strategies to control outbreaks and protect vulnerable groups Chan2023Fiore2011.
Conclusion
Antiviral medications, particularly neuraminidase inhibitors and baloxavir, are effective for treating influenza when started early, reducing symptom duration and complications. While older drugs like amantadine are less used due to resistance, new antivirals and combination therapies are being developed to address current limitations. Ongoing research aims to improve outcomes, especially for severe cases and high-risk patients, and to prevent the spread of influenza in the community Chan2023Hsu2012Koszalka2017+7 MORE.
Sources and full results
Most relevant research papers on this topic
Developing new antiviral agents for influenza treatment: what does the future hold?
New antiviral agents are urgently needed to overcome current limitations in influenza treatment, with potential targets including polymerase inhibitors and attachment inhibitors.
DOI